{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:23:52Z","timestamp":1767144232027,"version":"build-2238731810"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T00:00:00Z","timestamp":1425081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40261-014-0264-4","type":"journal-article","created":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T09:14:38Z","timestamp":1425028478000},"page":"229-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Health Economic Evaluation of Paricalcitol\u00ae Versus Cincalcet\u00a0+\u00a0Calcitriol (Oral) in Italy"],"prefix":"10.1007","volume":"35","author":[{"given":"Mark","family":"Nuijten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela P.","family":"Roggeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Roggeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,28]]},"reference":[{"issue":"3","key":"264_CR1","first-page":"418","volume":"15","author":"CO Alebiosu","year":"2005","unstructured":"Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. Ethn Dis. 2005;15(3):418\u201323.","journal-title":"Ethn Dis."},{"issue":"S15","key":"264_CR2","first-page":"S16","volume":"23","author":"P Zamboli","year":"2010","unstructured":"Zamboli P, De Nicola L, Conte G, Minutolo R. Epidemiology of chronic kidney disease in Italy. J Nephrol. 2010;23(S15):S16\u201322.","journal-title":"J Nephrol"},{"key":"264_CR3","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/sj.ki.5001641","volume":"70","author":"M Cirillo","year":"2006","unstructured":"Cirillo M, Laurenzi M, Mancini M, et al. Low glomerular filtration in the population: prevalence, associated disorders, and awareness. Kidney Int. 2006;70:800\u20136.","journal-title":"Kidney Int."},{"key":"264_CR4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/j.ajkd.2008.03.002","volume":"52","author":"R Minutolo","year":"2009","unstructured":"Minutolo R, De Nicola L, Mazzaglia G, et al. Detection and awareness of moderate to advanced chronic kidney disease in Italian primary care offices: a cross sectional study. Am J Kidney Dis. 2009;52:444\u201353.","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"264_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.ackd.2004.10.009","volume":"12","author":"SL White","year":"2005","unstructured":"White SL, Cass A, Atkins RC, Chadban SJ. Chronic kidney disease in the general population. Adv Chronic Kidney Dis. 2005;12(1):5\u201313.","journal-title":"Adv Chronic Kidney Dis."},{"issue":"3","key":"264_CR6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.0894-0959.2004.17308.x","volume":"17","author":"WG Goodman","year":"2004","unstructured":"Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial. 2004;17(3):209\u201316.","journal-title":"Semin Dial."},{"key":"264_CR7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000045533","volume":"84","author":"K Tsuchihashi","year":"2000","unstructured":"Tsuchihashi K, Takizawa H, Torii T, et al. Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism. Possible risk of vitamin D3 analog administration in dialysis patients with end-stage renal disease. Nephron. 2000;84:13\u201320.","journal-title":"Nephron."},{"key":"264_CR8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/j.1875-9114.1996.tb03644.x","volume":"16","author":"RE Daisley-Kydd","year":"1996","unstructured":"Daisley-Kydd RE, Mason NA. Calcitriol in the management of secondary hyperparathyroidism of renal failure. Pharmacotherapy. 1996;16:619\u201330.","journal-title":"Pharmacotherapy."},{"key":"264_CR9","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1053\/ajkd.2000.19812","volume":"36","author":"M Coco","year":"2000","unstructured":"Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36:1115\u201321.","journal-title":"Am J Kidney Dis."},{"key":"264_CR10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00000441-200008000-00007","volume":"320","author":"M Yudd","year":"2000","unstructured":"Yudd M, Llach F. Current medical management of secondary hyperparathyroidism. Am J Med Sci. 2000;320:100\u20136.","journal-title":"Am J Med Sci."},{"key":"264_CR11","first-page":"291","volume":"97","author":"SN Tuma","year":"1981","unstructured":"Tuma SN, Martin RR, Mallette LE, Eknoyan G. Augmented polymorphonuclear chemiluminescence in patients with secondary hyperparathyroidism. J Lab Clin Med. 1981;97:291\u20138.","journal-title":"J Lab Clin Med"},{"key":"264_CR12","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/ki.1992.219","volume":"41","author":"I Chervu","year":"1992","unstructured":"Chervu I, Kiersztein M, Alexiewicz JM, Fadda GZ, Smogorzewski M, Massry SG. Impaired phagocytosis in chronic renal failure is mediated by secondary hyperparathyroidism. Kidney Int. 1992;41:1501\u20135.","journal-title":"Kidney Int."},{"key":"264_CR13","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0272-6386(97)90484-4","volume":"30","author":"S Bro","year":"1997","unstructured":"Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis. 1997;30:606\u201320.","journal-title":"Am J Kidney Dis."},{"key":"264_CR14","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0272-6386(98)70080-0","volume":"32","author":"S Huraib","year":"1998","unstructured":"Huraib S, Tanimu D, Romeh SA, et al. Effects of intravenous alfacalcidol on lymphocyte phenotyping in hemodialysis patients. Am J Kidney Dis. 1998;32:1036\u201340.","journal-title":"Am J Kidney Dis."},{"key":"264_CR15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0272-6386(86)80132-9","volume":"7","author":"D Rubinger","year":"1986","unstructured":"Rubinger D, Friedlander MM, Silver J, Koplovic Y, Czaczkes WJ, Popovtzer MM. Progressive vascular calcification with necrosis of extremities in hemodialysis patients: a possible role of iron overload. Am J Kidney Dis. 1986;7:125\u20139.","journal-title":"Am J Kidney Dis."},{"issue":"Suppl 5","key":"264_CR16","doi-asserted-by":"crossref","first-page":"V2","DOI":"10.1093\/ndt\/gfh1049","volume":"19","author":"WH Horl","year":"2004","unstructured":"Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant. 2004;19(Suppl 5):V2\u20138.","journal-title":"Nephrol Dial Transplant."},{"key":"264_CR17","first-page":"165","volume":"15","author":"M Gallieni","year":"2002","unstructured":"Gallieni M, Cucciniello E, D\u2019Amaro E, et al. Calcium, phosphate and PTH levels in the HD population: a multicenter study. J Nephrol. 2002;15:165\u201370.","journal-title":"J Nephrol."},{"issue":"Suppl 3","key":"264_CR18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/ndt\/13.suppl_3.51","volume":"13","author":"C D\u00edaz-Corte","year":"1998","unstructured":"D\u00edaz-Corte C, Naves Diaz ML, Gomez Alonso C, Barreto S, Cannata Andia JB. Prevention, diagnosis and treatment of renal osteodystrophy in Spain. Preliminary results from a multicentre enquiry. Nephrol Dial Transplant. 1998;13(Suppl 3):51\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"264_CR19","doi-asserted-by":"crossref","unstructured":"Llach F, Velasquez-Forero F. Secondary Hyperparathyroidism in chronic renal failure; pathogenic and clinical aspects. Am J Kidney Dis. 2001;38(5):Suppl 5 S20\u2013S33.","DOI":"10.1053\/ajkd.2001.28113"},{"issue":"02","key":"264_CR20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5301\/JN.2010.6193","volume":"24","author":"S Mazzaferro","year":"2011","unstructured":"Mazzaferro S, Brancaccio D, Messa P, FARO Study Group, et al. Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey. J Nephrol. 2011;24(02):225\u201335.","journal-title":"J Nephrol."},{"key":"264_CR21","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/0272-6386(95)90455-7","volume":"26","author":"E Slatopolsky","year":"1995","unstructured":"Slatopolsky E, Finch J, Ritter C, et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kid Dis 1995;26:852\u201360.","journal-title":"Am J Kid Dis"},{"key":"264_CR22","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","volume":"10","author":"J Finch","year":"1999","unstructured":"Finch J, Brown A, Slatolpolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999;10:980\u20135.","journal-title":"J Am Soc Nephrol"},{"key":"264_CR23","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","volume":"40","author":"DW Coyne","year":"2002","unstructured":"Coyne DW, Grieff M, Ahya SN, et al. Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002;40:1283\u20138.","journal-title":"Am J Kidney Dis"},{"key":"264_CR24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","volume":"9","author":"KJ Martin","year":"1998","unstructured":"Martin KJ, Gonzales EA, Gellens M, et al. 19-Nor-1-a-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427\u201332.","journal-title":"J Am Soc Nephrol"},{"key":"264_CR25","first-page":"315","volume":"56","author":"J Lindberg","year":"2001","unstructured":"Lindberg J, Martin KJ, Gonzalez EA, et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001;56:315\u201323.","journal-title":"Clin Nephrol"},{"key":"264_CR26","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"S Sprague","year":"2003","unstructured":"Sprague S, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483\u201390.","journal-title":"Kidney Int"},{"key":"264_CR27","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","volume":"38","author":"F Llach","year":"2001","unstructured":"Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriolresistant secondary hyperparathyroidism. Am J Kidney Dis 2001;38:S45\u201350.","journal-title":"Am J Kidney Dis"},{"key":"264_CR28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus J, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446\u201356.","journal-title":"N Engl J Med."},{"key":"264_CR29","unstructured":"Valutazione di qualit\u00e0 dell\u2019attivit\u00e0 del trapianto di Rene 2000\u20132008\u2014Rete Nazionale Trapianti e Centro nazionale Trapianti. http:\/\/www.trapianti.salute.gov.it\/imgs\/C_17_pubblicazioni_1476_ulterioriallegati_ulterioreallegato_1_alleg.pdf . Accessed 5 Aug 2012."},{"issue":"3","key":"264_CR30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.mcna.2004.11.001","volume":"89","author":"K Zandi-Nejad","year":"2005","unstructured":"Zandi-Nejad K, Brenner BM. Strategies to retard the progression of chronic kidney disease. Med Clin North Am. 2005;89(3):489\u2013509.","journal-title":"Med Clin North Am."},{"issue":"5","key":"264_CR31","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.ajkd.2003.06.001","volume":"42","author":"TC Mix","year":"2003","unstructured":"Mix TC, Stpeter WL, Ebben J, Xue J, Pereira BJ, Kausz AT, Collins AJ. Hospitalization during advancing chronic kidney disease. Am J Kidney Dis. 2003;42(5):972\u201381.","journal-title":"Am J Kidney Dis."},{"issue":"8","key":"264_CR32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2165\/11536310-000000000-00000","volume":"30","author":"M Nuijten","year":"2010","unstructured":"Nuijten M, Andress DL, Marx SE, Curry AS, Sterz R. Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin Drug Investig. 2010;30(8):545\u201357.","journal-title":"Clin Drug Investig."},{"issue":"5","key":"264_CR33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1185\/03007990902844097","volume":"25","author":"M Nuijten","year":"2009","unstructured":"Nuijten M, Andress DL, Marx SE, Sterz R. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin. 2009;25(5):1221\u201334.","journal-title":"Curr Med Res Opin."},{"issue":"6","key":"264_CR34","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3111\/13696998.2012.703632","volume":"15","author":"DP Roggeri","year":"2012","unstructured":"Roggeri DP, Mazzaferro S, Brancaccio D, et al. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study. J Med Econ. 2012;15(6):1110\u20137.","journal-title":"J Med Econ."},{"key":"264_CR35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00019053-199814040-00009","volume":"4","author":"MJC Nuijten","year":"1998","unstructured":"Nuijten MJC. Cost-effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics. 1998;4:433\u201355.","journal-title":"Pharmacoeconomics."},{"key":"264_CR36","first-page":"1197","volume-title":"Quality of life and pharmacoeconomics in clinical trials","author":"J Barr","year":"1996","unstructured":"Barr J, Schumacher GE. Using decision analysis to conduct pharmacoeconomic studies. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven; 1996. p. 1197\u2013214."},{"key":"264_CR37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"F Sonnenberg","year":"1993","unstructured":"Sonnenberg F, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322\u201338.","journal-title":"Med Decis Making."},{"key":"264_CR38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/009286150103500122","volume":"35","author":"S Capri","year":"2001","unstructured":"Capri S, Ceci A, Teraanova L, Merlo F, Mantovani LG. Guidelines for economic evaluations in Italy: recommendations from the Italian Group of Pharmaeconomic Studies. Drug Inf J. 2001;35:189\u2013201.","journal-title":"Drug Inf J"},{"key":"264_CR39","unstructured":"IMS Italy, 2013."},{"issue":"2","key":"264_CR40","first-page":"91","volume":"10","author":"Gruppo di Lavoro coordinato da Giovanni Fattore","year":"2009","unstructured":"Gruppo di Lavoro coordinato da Giovanni Fattore. Associazione Italiana di Economia Sanitaria Proposta di linee guida per la valutazione economica degli interventi sanitari. Politiche Sanitarie. 2009;10(2):91\u20139.","journal-title":"Politiche Sanitarie."},{"key":"264_CR41","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","volume":"5","author":"D Dobrez","year":"2004","unstructured":"Dobrez D, Mathes A, Amdahl M, Marx S, Melnick J, Sprague S. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004;5:1174\u201381.","journal-title":"Nephrol Dial Transplant."},{"key":"264_CR42","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","volume":"68","author":"J Cunningham","year":"2005","unstructured":"Cunningham J, Danese MD, Olson KA, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCI on cardiovascular disease, fracture, and health related quality of life in secondary hyperparathryoidism. Kidney Int. 2005;68:1793\u2013800.","journal-title":"Kidney Int."},{"key":"264_CR43","unstructured":"Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess. 2007;11(18):iii, xi\u2013xiii, 1\u2013167."},{"issue":"24","key":"264_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9240","volume":"9","author":"P Roderick","year":"2005","unstructured":"Roderick P, Nicholson T, Armitage A, Mehta R, Mullee M, Gerard K, et al. An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales. Health Technol Assess. 2005;9(24):1\u2013178.","journal-title":"Health Technol Assess."},{"issue":"12","key":"264_CR45","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1093\/ndt\/gfs400","volume":"27","author":"M Ketteler","year":"2012","unstructured":"Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012;27(12):4298\u2013307.","journal-title":"Nephrol Dial Transplant."},{"key":"264_CR46","doi-asserted-by":"crossref","unstructured":"Cicchetti A, Ruggeri M, Codella P, et al. I costi socio-sanitari dell\u2019insufficienza renale cronica. Farmeconomia e Percorsi Terapeutici. 2011;12(1):21\u201328.","DOI":"10.7175\/fe.v12i1.95"},{"key":"264_CR47","unstructured":"I costi associati al trapianto di rene\u2014Progetto di ricerca, inanziato da Fondazione IRCCS Policlinico San Matteo. Progetto Bocconi\u2014IRCCS S.Matteo."},{"key":"264_CR48","unstructured":"Inflazione Italia anno 2012. http:\/\/epp.eurostat.ec.europa.eu\/pls\/portal\/docs\/PAGE\/PGP_DS_HICP\/TAB61582098\/04%20METHHICP%20CM%20-%20ITALY%202007-11.PDF (updated link http:\/\/www.rivaluta.it\/inflazione\/inflazione-2012.htm ). Accessed 5 Aug 2012."},{"key":"264_CR49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00019053-199813030-00005","volume":"3","author":"M Nuijten","year":"1998","unstructured":"Nuijten M. Data management in modelling studies: the selection of data sources. Pharmacoeconomics. 1998;3:305\u201316.","journal-title":"Pharmacoeconomics."},{"issue":"3","key":"264_CR50","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W","volume":"6","author":"MJ Buxton","year":"1997","unstructured":"Buxton MJ, Drummond MF, van Hout B. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6(3):217\u201328.","journal-title":"Health Econ."},{"issue":"13","key":"264_CR51","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00019053-200321130-00003","volume":"21","author":"MJ Nuijten","year":"2003","unstructured":"Nuijten MJ, Rutten F. The incorporation of potential confounding variables in Markov models. Pharmacoeconomics. 2003;21(13):941\u201350.","journal-title":"Pharmacoeconomics."},{"key":"264_CR52","unstructured":"AIFA. http:\/\/farmaco.agenziafarmaco.it\/index.php . Accessed 5 Aug 2012."},{"key":"264_CR53","unstructured":"Tariffa Unica Convenzionata anno 2010. http:\/\/www.ospfe.it\/il-professionista\/ufficio-dimissioni-ospedaliereinfo-e-strumenti\/tuc-tariffa-unica-concordata (updated link http:\/\/www.saluter.it\/siseps\/sanita\/sdo\/files\/tariffario%20_DRG_TUC2010_definitivo.xls ). Accessed 5 Aug 2012."}],"updated-by":[{"DOI":"10.1007\/s40261-015-0284-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T00:00:00Z","timestamp":1427328000000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0264-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-014-0264-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0264-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T09:33:16Z","timestamp":1717752796000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-014-0264-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,28]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["264"],"URL":"https:\/\/doi.org\/10.1007\/s40261-014-0264-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,28]]}}}